# Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

> **NCT00554827** · PHASE1 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 55 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic Acid
- **DRUG:** Pralatrexate

## Key facts

- **NCT ID:** NCT00554827
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-02
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554827, "Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00554827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*